Hengrui Medicine stock: China approves new antibody drug launch

Published on 11/13/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hengrui Medicine stock is in focus after China approved a new antibody drug for launch. The decision broadens its cardiovascular pipeline.

Hengrui advances its drug pipeline

China's NMPA approved the market launch of a Hengrui-developed Class 1 monoclonal antibody for patients with homozygous familial hypercholesterolemia.
The approval expands Hengrui's portfolio in cardiovascular and metabolic medicine while the company continues to build an international pipeline.
Investors will focus on the commercial rollout and further regulatory progress across Hengrui's late-stage programs.

Bank of Shanghai, CNE0000014W7, Illustration mit AI erstellt.

Jiangsu Hengrui Medicine has received Chinese regulatory approval to launch a new Class 1 monoclonal antibody, adding a late-stage product to its cardiovascular and metabolic medicine portfolio. The approval was reported on Thursday, November 12, 2026, by Zhitong Finance in a report carried by Futu.

New approval targets cardiovascular disease

Beijing Shengdi Pharmaceutical, a Hengrui subsidiary, received notice from China's National Medical Products Administration approving the launch of the antibody injection. The report identifies the product as Revexibai monoclonal antibody injection and describes it as an independently developed Class 1 new drug.

The medicine targets angiopoietin-like protein 3, or ANGPTL3. By inhibiting that pathway, it is intended to lower serum triglyceride and low-density lipoprotein cholesterol levels. The approval was based on a randomized, double-blind, placebo-controlled Phase III study in patients aged at least 12 with homozygous familial hypercholesterolemia.

Commercial execution remains key

The regulatory decision moves the program from clinical development toward commercialization. The company will now need to translate the approval into supply, market access and physician adoption, while investors assess how the new product fits into Hengrui's broader innovative-drug portfolio.

The report notes that Regeneron's evinacumab is an approved drug targeting the same pathway in overseas markets. That reference highlights the commercial opportunity in a specialized lipid-disorder market, but does not establish the size of Hengrui's future sales or the product's competitive share.

China's biopharma competition

Hengrui is a China-based biopharmaceutical company headquartered in Lianyungang. Its operations span drug discovery, clinical development, manufacturing and international distribution, with programs focused on oncology, metabolic and cardiovascular diseases, immune and respiratory conditions, neuroscience and pain management.

In China's innovative-drug sector, Hengrui operates alongside competitors including Innovent Biologics, Hansoh Pharma and BeOne Medicines. Fierce Biotech describes Hengrui as one of China's established biopharma companies, while those peers are also expanding innovative pipelines and international partnerships.